News & Updates

Show Multimedia Only

Can fasting and a no-sugar diet alleviate long COVID symptoms?

19 Aug 2025 by

In a crossover trial evaluating the effect of two intermittent fasting (IF) regimens on long COVID (LC) symptoms, a daily 16-h fast with water-only fast and a no-sugar diet fared better than a daily 14-h time-restricted eating (TRE) regimen for mitigating long COVID symptoms.

Can fasting and a no-sugar diet alleviate long COVID symptoms?

19 Aug 2025

GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients

18 Aug 2025 by

New research suggests that in older adults with type 2 diabetes (T2D) who are taking metformin, using dipeptidyl peptidase-4 inhibitors (DPP4is) and glucagon-like peptide-1 receptor agonists (GLP1RAs) has a null effect on the risk of COVID-19 infection. However, among those who do contract the virus, the use of these drugs appears to lower the risk of hospitalization.

GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients

18 Aug 2025

Personalized approach may improve PrEP uptake in MSM, transgenders

18 Aug 2025 by

A recent study in the Philippines has identified key demographic and behavioural patterns among Filipino men who have sex with men (MSM) and transgender individuals (TGIs) regarding their awareness of pre-exposure prophylaxis (PrEP) and modality preferences.

Personalized approach may improve PrEP uptake in MSM, transgenders

18 Aug 2025

Hormone therapy use has no bearing on severe COVID-19 outcomes

17 Aug 2025

A recent study suggests that the use of hormone therapy does not contribute to increased women with severe symptoms of COVID-19.

Hormone therapy use has no bearing on severe COVID-19 outcomes

17 Aug 2025

Advancing collaboration in COVID-19 care

16 Aug 2025

Held in June 2025 in Singapore, the Pfizer COVID-CONNECT Masterclass convened international experts to discuss the evolving challenges of COVID-19. Co-chaired by Dr Asok Kurup and Dr Luke Moore, this event assessed the ongoing global impact of the disease and explored evidence-based strategies across the patient journey from early identification to effective treatment.

Advancing collaboration in COVID-19 care

16 Aug 2025

Oseltamivir for influenza helps reduce neuropsychiatric events

15 Aug 2025

The use of oseltamivir for treating influenza episodes in children appears to lower the risk of serious neuropsychiatric events, according to a retrospective cohort study.

Oseltamivir for influenza helps reduce neuropsychiatric events

15 Aug 2025

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

At the recent COVID-CONNECT Masterclass, an expert-led session explored where COVID-19 stands among common viral infections today. In a non-promotional symposium supported by Pfizer, infectious disease specialist Dr Leong Hoe Nam, Mount Elizabeth Hospital Novena, Singapore, discussed strategies for managing viral infections and surge preparedness. Complementing this, Professor David Strain from the University of Exeter Medical School, UK highlighted the enduring burden of long COVID.

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

14 Aug 2025 by

The E-STOP trial presented at ESHRE 2025 supports early antibiotic suspension in paediatric patients with cancer and febrile neutropenia (FN).

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

14 Aug 2025

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

13 Aug 2025 by

The IMPROVE trial shows the feasibility and safety of 1-month isoniazid and rifapentine (1HP) in an inpatient setting as tuberculosis preventive therapy (TPT) in patients with advanced HIV disease (AHD) and cryptococcal meningitis (CM).

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

13 Aug 2025

F/TAF + cobicistat-boosted PIs maintained virologic suppression in children with HIV

13 Aug 2025 by

Treatment with emtricitabine/tenofovir alafenamide (F/TAF) and cobicistat-boosted atazanavir (ATV/c) or darunavir (DRV/c) maintained high rates of virologic suppression through 48 weeks in children living with HIV, based on two cohorts from the GS-US-216-0128 study presented at IAS 2025.

F/TAF + cobicistat-boosted PIs maintained virologic suppression in children with HIV

13 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

Can fasting and a no-sugar diet alleviate long COVID symptoms?

Can fasting and a no-sugar diet alleviate long COVID symptoms?

GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients

GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients

Personalized approach may improve PrEP uptake in MSM, transgenders

Personalized approach may improve PrEP uptake in MSM, transgenders

Hormone therapy use has no bearing on severe COVID-19 outcomes

Hormone therapy use has no bearing on severe COVID-19 outcomes

Advancing collaboration in COVID-19 care

Advancing collaboration in COVID-19 care

Oseltamivir for influenza helps reduce neuropsychiatric events

Oseltamivir for influenza helps reduce neuropsychiatric events

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

F/TAF + cobicistat-boosted PIs maintained virologic suppression in children with HIV

F/TAF + cobicistat-boosted PIs maintained virologic suppression in children with HIV